Skip to main content
Erschienen in: Supportive Care in Cancer 1/2024

01.01.2024 | Review

Representation of race and ethnicity among cancer survivors in trials of cognitive behavioral therapy for insomnia (CBT-I): A systematic review

verfasst von: Raissa Li, Yan Ma, Kimberly A. Arditte Hall, Caetlin Johnson, Lisa L. Philpotts, Giselle K. Perez, Elyse R. Park, Daniel L. Hall

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For cancer survivors, insomnia is highly prevalent and debilitating. Although cognitive behavioral therapy for insomnia (CBT-I) is recognized as a gold standard treatment, it is unclear whether benefits of treatment generalize to racial and ethnic minorities in the USA. This systematic review characterizes the representation of racial and ethnic diversity among cancer survivors in CBT-I clinical trials and provides recommendations for research in sleep/cancer survivorship.

Methods

Literature searches were conducted in five electronic databases (PubMed, Cochrane Library via Ovid, PsycINFO via Ovid, Embase, Web of Science Core Collection) using concepts of CBT, insomnia, and cancer survivors. Information about CBT-I intervention details, sample racial demographics, and whether authors explicitly analyzed race and ethnicity were recorded.

Results

A total of 1673 citations were retrieved, and 967 citations were uploaded to Covidence. Of these, 135 articles went through full-text review and 13 studies were included. Race and ethnicity were reported in 11/13 trials (84.6%). Of those reporting race and ethnicity, 8/11 (72.7%) trials were comprised of samples that were ≥ 85% non-Hispanic White. Among the trials that explicitly analyzed race and ethnicity, CBT-I was more effective among cancer survivors who were White and highly educated, and non-White cancer survivors were less likely to have private insurance and ability to participate in clinical trials.

Conclusion

Non-Hispanic White cancer survivors are overrepresented in CBT-I trials, the best available treatment for insomnia. Underrepresentation of racial and ethnic minorities likely contributes to barriers in access and uptake. Recommendations include implementing sustained efforts to expand diversity in CBT-I clinical trials for cancer survivors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Stepanski EJ (2005) Hypnotics should not be considered for the initial treatment of chronic insomnia. Con J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 1(2):125–8 Stepanski EJ (2005) Hypnotics should not be considered for the initial treatment of chronic insomnia. Con J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 1(2):125–8
13.
Zurück zum Zitat Perlis ML (2005) Cognitive behavioral treatment of insomnia: a session-by-session guide. Springer, New York, New York Perlis ML (2005) Cognitive behavioral treatment of insomnia: a session-by-session guide. Springer, New York, New York
16.
Zurück zum Zitat Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL et al (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 17(2):255–262. https://doi.org/10.5664/jcsm.8986CrossRef Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL et al (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 17(2):255–262. https://​doi.​org/​10.​5664/​jcsm.​8986CrossRef
26.
Zurück zum Zitat Matthews EE, Berger AM, Schmiege SJ, Cook PF, McCarthy MS, Moore CM et al (2014) Cognitive behavioral therapy for insomnia outcomes in women after primary breast cancer treatment: a randomized, controlled trial. Oncol Nurs Forum 1;41(3):241–53. https://doi.org/10.1188/14.ONF.41-03AP Matthews EE, Berger AM, Schmiege SJ, Cook PF, McCarthy MS, Moore CM et al (2014) Cognitive behavioral therapy for insomnia outcomes in women after primary breast cancer treatment: a randomized, controlled trial. Oncol Nurs Forum 1;41(3):241–53. https://​doi.​org/​10.​1188/​14.​ONF.​41-03AP
28.
Zurück zum Zitat Arem H, Lewin D, Cifu G, Bires J, Goldberg E, Kaltman R et al (2019) A feasibility study of group-delivered behavioral interventions for insomnia among breast cancer survivors: comparing cognitive behavioral therapy for insomnia and a mind–body intervention. J Altern Complement Med 25(8):840–844. https://doi.org/10.1089/acm.2019.0038CrossRefPubMed Arem H, Lewin D, Cifu G, Bires J, Goldberg E, Kaltman R et al (2019) A feasibility study of group-delivered behavioral interventions for insomnia among breast cancer survivors: comparing cognitive behavioral therapy for insomnia and a mind–body intervention. J Altern Complement Med 25(8):840–844. https://​doi.​org/​10.​1089/​acm.​2019.​0038CrossRefPubMed
29.
Zurück zum Zitat Fiorentino L, McQuaid Liu, Natarajan He, Cornejo et al (2009) Individual cognitive behavioral therapy for insomnia in breast cancer survivors: a randomized controlled crossover pilot study. Nat Sci Sleep 1. https://doi.org/10.2147/NSS.S8004 Fiorentino L, McQuaid Liu, Natarajan He, Cornejo et al (2009) Individual cognitive behavioral therapy for insomnia in breast cancer survivors: a randomized controlled crossover pilot study. Nat Sci Sleep 1. https://​doi.​org/​10.​2147/​NSS.​S8004
35.
38.
Zurück zum Zitat Geiss C, Chavez MN, Oswald LB, Ketcher D, Reblin M, Bandera EV et al (2022) “I beat cancer to feel sick:” qualitative experiences of sleep disturbance in black breast cancer survivors and recommendations for culturally targeted sleep interventions. Ann Behav Med Publ Soc Behav Med 56(11):1110–1115. https://doi.org/10.1093/abm/kaac035CrossRef Geiss C, Chavez MN, Oswald LB, Ketcher D, Reblin M, Bandera EV et al (2022) “I beat cancer to feel sick:” qualitative experiences of sleep disturbance in black breast cancer survivors and recommendations for culturally targeted sleep interventions. Ann Behav Med Publ Soc Behav Med 56(11):1110–1115. https://​doi.​org/​10.​1093/​abm/​kaac035CrossRef
46.
Zurück zum Zitat The National Academies of Sciences, Engineering, and Medicine (2022) Improving representation in clinical trials and research: building research equity for women and underrepresented groups. : The National Academies Press. Washington, DC. 260. pp 15-23 The National Academies of Sciences, Engineering, and Medicine (2022) Improving representation in clinical trials and research: building research equity for women and underrepresented groups. : The National Academies Press. Washington, DC. 260. pp 15-23
47.
Zurück zum Zitat Langford AT, Resnicow K, Dimond EP, Denicoff AM, Germain DST, McCaskill-Stevens W et al (2014) Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer 120(6):877–84. https://doi.org/10.1002/cncr.28483CrossRefPubMed Langford AT, Resnicow K, Dimond EP, Denicoff AM, Germain DST, McCaskill-Stevens W et al (2014) Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer 120(6):877–84. https://​doi.​org/​10.​1002/​cncr.​28483CrossRefPubMed
48.
Zurück zum Zitat Perez GK, Rabin JT, Tandon M, Strauss NM, Irwin K, Philpotts L et al (2023) Do tobacco treatment trials address disparities in smoking outcomes among Black and Hispanic cancer patients? A systematic review of smoking cessation interventions for Black and Hispanic patients diagnosed with cancer. J Racial Ethn Health Disparities https://doi.org/10.1007/s40615-023-01705-3 Perez GK, Rabin JT, Tandon M, Strauss NM, Irwin K, Philpotts L et al (2023) Do tobacco treatment trials address disparities in smoking outcomes among Black and Hispanic cancer patients? A systematic review of smoking cessation interventions for Black and Hispanic patients diagnosed with cancer. J Racial Ethn Health Disparities https://​doi.​org/​10.​1007/​s40615-023-01705-3
50.
Zurück zum Zitat Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N et al (2022) Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J Clin Oncol Off J Am Soc Clin Oncol 40(19):2163–2171. https://doi.org/10.1200/JCO.22.00754CrossRef Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N et al (2022) Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J Clin Oncol Off J Am Soc Clin Oncol 40(19):2163–2171. https://​doi.​org/​10.​1200/​JCO.​22.​00754CrossRef
Metadaten
Titel
Representation of race and ethnicity among cancer survivors in trials of cognitive behavioral therapy for insomnia (CBT-I): A systematic review
verfasst von
Raissa Li
Yan Ma
Kimberly A. Arditte Hall
Caetlin Johnson
Lisa L. Philpotts
Giselle K. Perez
Elyse R. Park
Daniel L. Hall
Publikationsdatum
01.01.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-08207-2

Weitere Artikel der Ausgabe 1/2024

Supportive Care in Cancer 1/2024 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.